Emami Ltd
Emami is engaged in manufacturing & marketing of personal care & healthcare products with an enviable portfolio of household brand names such as BoroPlus, Navratna, Fair and Handsome, Zandu Balm, Kesh King, Zandu Pancharishta, Mentho Plus Balm and others.(Source : 201903 Annual Report Page No: 193)
- Market Cap ₹ 19,173 Cr.
- Current Price ₹ 439
- High / Low ₹ 589 / 358
- Stock P/E 26.6
- Book Value ₹ 55.1
- Dividend Yield 1.82 %
- ROCE 28.0 %
- ROE 28.3 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 31.4%
- Company has been maintaining a healthy dividend payout of 58.5%
Cons
- Stock is trading at 7.97 times its book value
- The company has delivered a poor sales growth of 6.12% over past five years.
- Tax rate seems low
- Debtor days have increased from 36.8 to 44.4 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: FMCG Industry: Personal Care - Indian
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1,370 | 1,595 | 1,700 | 2,076 | 2,358 | 2,488 | 2,531 | 2,695 | 2,655 | 2,881 | 3,192 | 3,406 | 3,523 | |
1,096 | 1,252 | 1,255 | 1,536 | 1,670 | 1,729 | 1,812 | 1,970 | 1,970 | 2,000 | 2,254 | 2,550 | 2,587 | |
Operating Profit | 274 | 343 | 445 | 541 | 688 | 759 | 719 | 725 | 685 | 880 | 938 | 855 | 936 |
OPM % | 20% | 22% | 26% | 26% | 29% | 31% | 28% | 27% | 26% | 31% | 29% | 25% | 27% |
58 | 54 | 53 | 91 | 44 | 31 | 19 | 25 | 46 | 69 | 90 | 69 | 44 | |
Interest | 15 | 7 | 5 | 5 | 54 | 58 | 34 | 21 | 21 | 13 | 5 | 7 | 8 |
Depreciation | 19 | 22 | 35 | 34 | 255 | 309 | 311 | 325 | 336 | 367 | 335 | 247 | 202 |
Profit before tax | 299 | 369 | 457 | 592 | 423 | 424 | 393 | 403 | 374 | 569 | 688 | 670 | 769 |
Tax % | 13% | 15% | 12% | 18% | 14% | 20% | 22% | 25% | 19% | 20% | -22% | 6% | |
259 | 315 | 402 | 485 | 363 | 340 | 306 | 303 | 302 | 455 | 837 | 627 | 719 | |
EPS in Rs | 5.70 | 6.93 | 8.87 | 10.70 | 8.00 | 7.50 | 6.77 | 6.68 | 6.67 | 10.23 | 19.02 | 14.50 | 16.42 |
Dividend Payout % | 47% | 38% | 39% | 33% | 44% | 47% | 52% | 60% | 60% | 78% | 42% | 55% |
Compounded Sales Growth | |
---|---|
10 Years: | 8% |
5 Years: | 6% |
3 Years: | 9% |
TTM: | 5% |
Compounded Profit Growth | |
---|---|
10 Years: | 7% |
5 Years: | 11% |
3 Years: | 28% |
TTM: | -15% |
Stock Price CAGR | |
---|---|
10 Years: | 6% |
5 Years: | 2% |
3 Years: | -5% |
1 Year: | 21% |
Return on Equity | |
---|---|
10 Years: | 27% |
5 Years: | 25% |
3 Years: | 31% |
Last Year: | 28% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 15 | 15 | 23 | 23 | 23 | 23 | 23 | 45 | 45 | 44 | 44 | 44 | 44 |
Reserves | 692 | 762 | 909 | 1,208 | 1,589 | 1,732 | 1,991 | 2,031 | 1,778 | 1,718 | 2,032 | 2,259 | 2,362 |
156 | 115 | 38 | 36 | 671 | 473 | 326 | 110 | 210 | 101 | 282 | 91 | 107 | |
315 | 324 | 333 | 410 | 409 | 376 | 458 | 633 | 644 | 656 | 692 | 703 | 806 | |
Total Liabilities | 1,177 | 1,216 | 1,302 | 1,676 | 2,692 | 2,603 | 2,798 | 2,819 | 2,678 | 2,520 | 3,050 | 3,096 | 3,319 |
408 | 397 | 396 | 453 | 1,918 | 1,994 | 1,802 | 1,680 | 1,459 | 1,132 | 1,344 | 1,245 | 1,176 | |
CWIP | 77 | 47 | 12 | 29 | 67 | 22 | 30 | 36 | 8 | 6 | 3 | 6 | 3 |
Investments | 80 | 163 | 296 | 501 | 104 | 128 | 314 | 187 | 156 | 255 | 303 | 293 | 434 |
612 | 609 | 599 | 693 | 604 | 460 | 652 | 915 | 1,055 | 1,126 | 1,400 | 1,551 | 1,706 | |
Total Assets | 1,177 | 1,216 | 1,302 | 1,676 | 2,692 | 2,603 | 2,798 | 2,819 | 2,678 | 2,520 | 3,050 | 3,096 | 3,319 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
343 | 323 | 428 | 534 | 562 | 730 | 588 | 554 | 531 | 922 | 644 | 749 | |
-133 | -130 | -140 | -237 | -1,313 | -306 | -276 | -26 | -231 | -224 | -234 | -122 | |
-145 | -188 | -301 | -215 | 502 | -496 | -324 | -428 | -405 | -688 | -402 | -608 | |
Net Cash Flow | 65 | 5 | -13 | 82 | -249 | -72 | -12 | 100 | -106 | 9 | 8 | 19 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 27 | 26 | 17 | 18 | 20 | 14 | 22 | 29 | 42 | 29 | 37 | 44 |
Inventory Days | 65 | 58 | 76 | 59 | 68 | 83 | 87 | 88 | 102 | 118 | 121 | 100 |
Days Payable | 61 | 52 | 77 | 90 | 112 | 85 | 109 | 115 | 135 | 138 | 138 | 126 |
Cash Conversion Cycle | 31 | 32 | 16 | -13 | -24 | 12 | 1 | 2 | 9 | 10 | 19 | 18 |
Working Capital Days | -7 | -7 | -6 | -13 | 3 | -37 | 15 | 9 | 36 | 9 | 31 | 37 |
ROCE % | 35% | 42% | 50% | 61% | 30% | 23% | 22% | 19% | 18% | 29% | 31% | 28% |
Documents
Announcements
- Certificate Under Regulation 40(9) And 40(10) Of The SEBI (LODR) Regulations, 2015 8 Apr
- Compliance Certificate Under Regulation 7(3) Of SEBI (LODR) Regulations, 2015 For The Year Ended 31St March, 2024 4 Apr
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
4 Apr - Certificate received from M/s Maheshwari Datamatics Pvt. Ltd., Kolkata, Registrar and Share Transfer Agent of the company, confirming compliance of dematerialization as per section 74(5) …
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 29 Mar
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 28 Mar
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
Feb 2024Transcript PPT
-
Feb 2024TranscriptNotesPPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
Aug 2023TranscriptNotesPPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Nov 2022TranscriptNotesPPT
-
Aug 2022Transcript PPT
-
Jun 2022TranscriptNotesPPT
-
May 2022TranscriptNotesPPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
Jun 2021Transcript PPT
-
Feb 2021Transcript PPT
-
Feb 2021Transcript PPT
-
Nov 2020Transcript PPT
-
Aug 2020TranscriptNotesPPT
-
Aug 2020Transcript PPT
-
Jul 2020Transcript PPT
-
Feb 2020TranscriptPPT
-
Dec 2019TranscriptPPT
-
Nov 2019TranscriptPPT
-
Aug 2019Transcript PPT
-
May 2019TranscriptPPT
-
Jan 2019TranscriptPPT
-
Oct 2018Transcript PPT
-
Aug 2018Transcript PPT
-
Aug 2018TranscriptNotesPPT
-
May 2018TranscriptPPT
-
Jan 2018TranscriptNotesPPT
-
Nov 2017Transcript PPT
-
Feb 2017TranscriptPPT
-
Oct 2016TranscriptPPT
-
Aug 2016Transcript PPT
-
May 2016Transcript PPT
-
Jan 2016TranscriptPPT
Leadership in Niche segments:[1] Emami is one of the leading companies in the personal and healthcare segment with leadership in the niche Ayurvedic segment. The Company has a portfolio of 450+ products based on ayurvedic formulations.